ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-PO041

TLR9 Activation Induces Overproduction of Aberrantly Glycosylated IgA through the APRIL Mediated Pathway in IgA Nephropathy

Session Information

Category: Glomerular

  • 1001 Glomerular: Basic/Experimental Immunology and Inflammation

Authors

  • Makita, Yuko, Juntendo University Faculty of Medicine, Tokyo, Japan
  • Suzuki, Hitoshi, Juntendo University Faculty of Medicine, Tokyo, Japan
  • Nihei, Yoshihito, Juntendo University Faculty of Medicine, Tokyo, Japan
  • Julian, Bruce A., University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Novak, Jan, University of Alabama at Birmingham, Birmingham, Alabama, United States
  • Suzuki, Yusuke, Juntendo University Faculty of Medicine, Tokyo, Japan
Background

Involvement of Toll-like receptor 9 (TLR9) that play a key role in the innate immune system has been discussed in the pathogenesis of IgA nephropathy (IgAN). There are increasing evidences that galactose-deficient IgA1 (Gd-IgA1) and Gd-IgA1 containing immune complexes (ICs) have critical roles in the pathogenesis of IgAN. We recently demonstrated that interleukin-6 (IL-6) can enhance the production of Gd-IgA1 by IgA1-producing cells. Moreover, A proliferation-inducing ligand (APRIL) may be involved in the overproduction of the nephritogenic IgA1. However, the mechanisms leading to overproduction of Gd-IgA1 and subsequent formation of Gd-IgA1 containing ICs are still unclear.

Methods

IgAN prone ddY mice were divided into two groups with CpG-ODN (TLR9 ligand) immunization (n=19) or without (n=19). CpG-ODN was injected intraperitoneally 3 times a week for 12 weeks. Renal pathology and serum levels of aberrantly glycosylated IgA (Gd-IgA), IgG-IgA ICs, IL-6 and APRIL were evaluated after 12 weeks. We also examined the mechanisms of production of Gd-IgA1 in human IgA1-secreting cells through TLR9 activation and stimulation with IL-6 and APRIL.

Results

Mice immunized with CpG-ODN, but not non-immunized mice, showed mesangioproliferative glomerulonephritis accompanied by mesangial deposition of IgA, and C3. Immunization with CpG-ODN elevated serum levels of Gd-IgA, IgG-IgA IC and APRIL (P<0.05). Serum levels of APRIL significantly correlated with serum level of Gd-IgA and IgG-IgA IC (P<0.05). The activation of TLR9 induced production of IL-6, and IL-6 stimulation induced overexpression of APRIL in splenocytes. Moreover, in human IgA1-secreting cells, TLR9 activation enhanced Gd-IgA1 production through overexpressions of IL-6 and APRIL. Production of Gd-IgA1 was reduced by anti-IL-6 and/or siRNA for APRIL. However, anti-IL-6 could not inhibit overproduction of APRIL completely.

Conclusion

TLR9 activation exacerbated murine IgAN by enhancing production of aberrantly glycosylated IgA and nephritogenic ICs. TLR9 activation induced overproduction of IL-6 and APRIL. Present study suggested that TLR9-induced overproduction of both IL-6 and APRIL resulted in enhancing production of Gd-IgA1 and subsequent formation of Gd-IgA1 containing ICs in IgAN.

Funding

  • Government Support - Non-U.S.